81
Participants
Start Date
September 9, 2019
Primary Completion Date
December 6, 2021
Study Completion Date
December 6, 2021
Placebo
Placebo vaginal inserts.
TOL-463
TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
Magee Women's Hospital of UPMC - Reproductive Infectious Disease Research, Pittsburgh
University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham
Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago
University of California, San Diego - Antiviral Research Center, La Jolla
National Institute of Allergy and Infectious Diseases (NIAID)
NIH